Sanofi SA (ADR) (NYSE:SNY) has been upgraded to Overweight in a statement by Morgan Stanley earlier today.
- Updated: November 29, 2016
Morgan Stanley has upgraded Sanofi SA (ADR) (NYSE:SNY) to Overweight in a statement released on Tuesday November 29, 2016.
On 02/10/2016, Bernstein released a statement for Sanofi SA (ADR) (NYSE:SNY) bumped down the target price from $52.00 to $45.00 that suggested an upside of 0.17%.
Boasting a price of $40.57, Sanofi SA (ADR) (NYSE:SNY) traded 1.79% higher on the day. With the last stock price close up 1.55% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the date range. Sanofi SA (ADR) has recorded a 50-day average of $39.23 and a two hundred day average of $39.82. Volume of trade was down over the average, with 2,218,324 shares of SNY changing hands under the typical 2,560,930
With a total market value of $0, Sanofi SA (ADR) has price-earnings ratio of 23.45 with a one year low of $36.81 and a one year high of $44.63 .
A total of 3 equity analysts have released a ratings update on the stock. 1 broker rating the stock a strong buy, 0 brokers rating the stock a buy, 2 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell with a consensus target price of $52.00.
General Information About Sanofi SA (ADR) (NYSE:SNY)
Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation. Its pharmaceuticals portfolio consists of products and a range of prescription medicines, generic medicines and consumer health products. The Vaccines segment is dedicated to vaccines, including research, development, production and marketing. The Animal Health segment includes the research, development, production and marketing activities of Merial, which offers a range of medicines and vaccines for a range of animal species. It also operates in the Other segment, which includes the effects of retained commitments in respect of divested activities.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.